S2U) has filed a patent application covering recent findings
documenting the existence of high concentrations of therapeutic
anti-inflammatory cells, called T regulatory cells, in fat tissue. The
findings, confirmed by Medistem collaborator Dr. Hao Wang at the Lawson
Health Research Institute, London, Canada, supports the possibility that
the therapeutic effects previously observed by other groups using fat stem
cells may be not be strictly due to the stem cells in the fat tissue but to
the T regulatory cell population.
"The patent application covers not only methods of using fat tissue for
suppressing inflammatory and autoimmunity, but also methods of expanding
and increasing activity of these therapeutic cells," said Neil Riordan PhD,
President and CEO of Medistem. He continued, "The current findings support
development of therapeutics that suppress diseases with the body's own
natural means, avoiding the need for toxic non-specific immune suppressants
and steroids. If treatments can be developed based on these findings,
patients could rely on T regulatory cells found in their own fat tissue,
instead of non-specific drugs."
Medistem is currently working with several academic collaborators to
develop regenerative and immune modulatory therapeutics using cellular
populations derived from the fat tissue, cord blood, and as recently
published, menstrual blood.
"Autoimmune diseases affect approximately 5-8 percent of the American
population, being the 3rd major cause of illness behind cancer and heart
disease. We are confident that our findings and intellectual property
positioning in this area may enable Medistem to start addressing a
substantially relevant unmet need," concluded Chris McGuinn, COO of
Medistem.
About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers, develops,
and commercializes adult stem cell products that address serious medical
conditions. While drug discovery and development is its primary focus,
Medistem has compiled a body of proprietary technologies it outlicenses to
commercial entities in markets where stem cell administration is
permissible. Due to its licensee relationships and collaborative efforts
with respected institutions, Medistem believes it is well positioned to be
a leading developer of adult stem cell products.
Cautionary Statement
This document does not constitute an offer to sell or a solicitation of an
offer to buy any of our securities. This document contains certain
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities
Exchange Act of 1934, as amended. These forward-looking statements may
include projections of matters that affect revenue, the ability to develop
or license certain technologies and receive associated licensing fees;
operating expenses or net earnings; projections of capital expenditures;
projections of growth; hiring plans; plans for future operations; financing
needs or plans; plans relating to the company's products and services; and
assumptions relating to the foregoing.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified. Future
events and actual results could differ materially from those set forth in,
contemplated by, or underlying the forward-looking information.
Some of the important factors that could cause the company's actual results
to differ materially from those projected in forward-looking statements
made by the company include, but are not limited to, the following: the
company's ability to anticipate future license fees, technology development
limitations, intense competition, risk of business interruption, management
of rapid growth, need for additional financing, regulatory approvals and
requirements, dependence on key personnel and research, management and
other administrative costs.
These factors are discussed in greater detail in the company's quarterly
and annual periodic reports, all as filed with the Securities and Exchange
Commission.